!psychedelic_therapy@lemmy.world
This is a place to discuss therapeutic use of various psychedelic substances, from ketamine to psilocybin to MDMA and others.
We welcome anything from personal accounts to scientific articles and talks.
The rules for posting and commenting, besides the rules defined here for lemmy.world, are as follows:
Rules
Posts containing medical advice or diagnosing others are not allowed. Please keep the post focused on your personal experience.
Please do not recommend specific dosages or treatment methods to others. It's OK to talk about your personal experience.
Harassment of any kind is not tolerated. Do not harass any user for any reason including treatment choices, race, religion, gender, sexuality, disability, etc.
We do not allow promotion, solicitation, or affiliate links. For interviews, surveys, and studies, please contact the moderators.
Related Communities
Community Moderation
For inquiry on becoming a moderator of this community, please send a message to the current moderators.
!psychedelic_therapy
@lemmy.worldhttps://bookshop.org/lists/books-for-psychedelic-therapy-and-exploration
https://www.pharmexec.com/view/study-suggests-promise-psilocybin-treating-depressive-symptoms
Findings from a recent study demonstrated that high-dose psilocybin provided a superior reduction in depressive symptoms compared to both placebo and escitalopram in patients with major depressive disorder.
https://www.psypost.org/lsd-reshapes-the-brains-response-to-pain-neuroimaging-study-finds/
LSD alters brain activity and connectivity in key regions associated with pain processing, offering potential insights for pain management and the therapeutic use of psychedelics.
https://www.liebertpub.com/doi/abs/10.1089/psymed.2024.0002?download=true&journalCode=psymed
https://www.nature.com/articles/s41598-024-68908-4
As a proposed mediator between stigma-related stressors and negative mental health outcomes, HIV-related shame has been predictive of increased rates of substance use and difficulties adhering to antiretroviral treatment among people with HIV. These downstream manifestations have ultimately impeded progress toward national goals to End the HIV Epidemic, in part due to limited success of conventional psychotherapies in addressing HIV-related shame. In a pilot clinical trial (N = 12), receipt of psilocybin-assisted group therapy was associated with a large pre-post decrease in HIV-related shame as measured by the HIV and Abuse Related Shame Inventory, with a median (IQR) change of − 5.5 (− 6.5, − 3.5) points from baseline to 3-months follow-up (Z = − 2.6, p = 0.009, r = − 0.75). A paradoxical exacerbation of sexual abuse-related shame experienced by two participants following receipt of psilocybin raises critical questions regarding the use of psilocybin therapy among patients with trauma. These preliminary findings carry potential significance for the future of HIV care.
https://www.cambridge.org/core/journals/the-british-journal-of-psychiatry/article/lsdassisted-therapy-in-patients-with-anxiety-openlabel-prospective-12month-followup/A4EF8F8A3F7B175B5AABF3EF7DB0AA69
LSD-assisted therapy in patients with anxiety: open-label prospective 12-month follow-up
https://doubleblindmag.com/psychedelic-mushroom-art?sca_ref=3452854.DodbjllPSh
Next time you find yourself lost in a psychedelic trip, gaze upon this art inspired by the colorful, vibrant world of mushrooms.
https://www.psypost.org/brain-imaging-study-sheds-light-on-how-magic-mushrooms-paint-vivid-images-behind-your-eyelids/
Neuroimaging research has found that psilocybin increases self-inhibition in visual brain regions and enhances top-down connectivity, leading to vivid, internally generated visual imagery with eyes closed.
https://www.psypost.org/the-science-of-magic-mushrooms-fascinating-findings-from-7-new-studies-of-psilocybin/
In recent years, the resurgence of interest in psychedelic substances has spotlighted psilocybin as a potential breakthrough in mental health treatment.